WHO to resume hydroxychloroquine coronavirus trials

Published June 4, 2020
ATHENS: An aerial view shows the opening night of a drive-in festival on Wednesday as Greece eases lockdown measures.—AFP
ATHENS: An aerial view shows the opening night of a drive-in festival on Wednesday as Greece eases lockdown measures.—AFP

GENEVA/THE HAGUE: The World Health Organisation announced on Wednesday that clinical trials of the drug hydroxychloroquine will resume as it searches for potential coronavirus treatments.

On May 25, the WHO announced it had temporarily suspended the trials to conduct a safety review, which has now concluded there is “no reason” to change the way the trials are conducted.

The UN health agency’s decision came after a study published in The Lancet medical journal suggesting the drug could increase the risk of death among Covid-19 patients.

The executive group of the so-called Solidarity Trial — in which hundreds of hospitals across the world have enrolled patients to test several possible treatments for the novel coronavirus — took the decision as a precaution.

Hydroxychloroquine is normally used to treat arthritis but public figures including US President Donald Trump have backed the drug for Covid-19 prevention and treatment, prompting governments to bulk-buy.

“Last week, the executive group of the Solidarity Trial decided to implement a temporary pause of the hydroxychloroquine arm of the trial, because of concerns raised about the safety of the drug,” WHO chief Tedros Adhanom Ghebreyesus told a virtual news briefing.

“This decision was taken as a precaution while the safety data were reviewed.

“The data safety and monitoring committee of the Solidarity Trial has been reviewing the data.

“On the basis of the available mortality data, the members of the committee recommended that there are no reasons to modify the trial protocol.

“The executive group received this recommendation and endorsed continuation of all arms of the Solidarity Trial, including hydroxychloroquine.

“The executive group will communicate with the principal investigators in the trial about resuming the hydroxychloroquine arm of the trial.

“The data safety and monitoring committee will continue to closely monitor the safety of all therapeutics being tested in the Solidarity Trial.” More than 3,500 patients have been recruited across 35 countries to take part in the trials.

Virus vaccine alliance

France, Germany, Italy and the Netherlands have forged an alliance to speed up the production of a vaccine “on European soil” against the new coronavirus, Dutch officials said on Wednesday.

Four of Europe’s largest economies “are jointly exploring various promising initiatives and are in discussion with various pharmaceutical companies,” the Dutch Health Ministry announced.

The aim of the “Inclusive Vaccine Alliance” was to allow for vaccine production on European soil wherever possible, the department said in a statement issued in The Hague.

Published in Dawn, June 4th, 2020

Opinion

Editorial

Ghastly attack
Updated 12 Oct, 2024

Ghastly attack

Duki attack comes at a time when Pakistan’s foreign friends are looking to make major investments in the country, while SCO moot kicks off next week.
Saudi investments
12 Oct, 2024

Saudi investments

THE Saudi investment commitments to Islamabad seem to be taking tangible shape after months of uncertainty around...
Into the abyss
12 Oct, 2024

Into the abyss

THE Pakistan cricket team continues to set unwanted records. On Friday, Shan Masood’s men became the first team in...
Disaffected voices
11 Oct, 2024

Disaffected voices

A FRESH stand-off is brewing between the state, and the recently banned PTM, principally over the tribal jirga that...
Joint anti-smog steps
11 Oct, 2024

Joint anti-smog steps

CLIMATE change knows no borders. Hence, much of the world is striving to control the rapidly rising global...
Agri taxes
11 Oct, 2024

Agri taxes

IT is not a good omen that reforms are once again being delayed. According to the finance minister, a new tax regime...